AVALO THERAPEUTICS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
AVALO THERAPEUTICS, INC. (AVTX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $7.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-08-06
- AVALO THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-06-30 was $7.58M, a 199.76% increase year-over-year.
- AVALO THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-03-31 was -$480.00K.
- AVALO THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-06-30 was $2.53M.
- AVALO THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-03-31 was -$380.00K.
- AVALO THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2025 was $9.52M.
- AVALO THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was -$118.68M.
- AVALO THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- AVALO THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2019 was $1.26M, a 1032.51% increase from fiscal 2018.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.58M 10-Q · filed 2026-08-06 | $7.10M derived: sum of 2 quarters · filed 2026-08-06 | ||||||
| 2026-03-31 | -$480.00K 10-Q · filed 2026-05-13 | |||||||
| 2025-12-31 | $9.52M 10-K · filed 2026-03-23 | |||||||
| 2025-06-30 | $2.53M 10-Q · filed 2026-08-06 | $2.15M derived: sum of 2 quarters · filed 2026-08-06 | -$77.15M derived: sum of 3 quarters · filed 2026-08-06 | |||||
| 2025-03-31 | -$380.00K 10-Q · filed 2026-05-13 | $79.30M 10-Q · filed 2025-05-12 | -$79.68M derived: sum of 2 quarters · filed 2026-05-13 | |||||
| 2024-12-31 | -$79.30M 10-K · filed 2026-03-23 | -$118.68M 10-K · filed 2026-03-23 | $79.30M 10-K · filed 2025-03-20 | |||||
| 2022-12-31 | -$79.30M 10-Q · filed 2025-11-06 | $79.30M 10-Q · filed 2025-08-07 | ||||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $0.00 derived: sum of 2 quarters · filed 2021-03-08 | $0.00 derived: sum of 3 quarters · filed 2021-03-08 | $0.00 10-K · filed 2021-03-08 | ||||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | $1.00 derived: sum of 4 quarters · filed 2021-03-08 | ||||
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $1.00 derived: sum of 3 quarters · filed 2021-03-08 | $1.00 derived: sum of 4 quarters · filed 2021-03-08 | ||||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 | $1.00 derived: sum of 2 quarters · filed 2021-03-08 | $1.00 derived: sum of 3 quarters · filed 2021-03-08 | $1.28M derived: sum of 4 quarters · filed 2021-03-08 | ||||
| 2019-12-31 | $1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $1.00 derived: sum of 2 quarters · filed 2021-03-08 | $1.28M derived: sum of 3 quarters · filed 2021-03-08 | $1.26M 10-K · filed 2021-03-08 | ||||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-09 | $197.22K 10-Q · filed 2019-11-14 | $1.28M derived: sum of 2 quarters · filed 2020-11-09 | $1.26M 10-Q · filed 2020-11-09 | $1.01M 10-Q · filed 2019-11-14 | $1.73M derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2019-06-30 | $1.28M 10-Q · filed 2020-08-06 | $992.35K 10-Q · filed 2019-08-08 | $1.26M 10-Q · filed 2020-08-06 | $811.95K 10-Q · filed 2019-08-08 | $1.73M derived: sum of 3 quarters · filed 2020-08-06 | $1.64M derived: sum of 4 quarters · filed 2020-08-06 | ||
| 2019-03-31 | -$20.94K 10-Q · filed 2020-05-07 | -$180.40K 10-Q · filed 2019-05-09 | $450.83K derived: sum of 2 quarters · filed 2020-05-07 | $365.99K derived: sum of 3 quarters · filed 2020-05-07 | $352.75K derived: sum of 4 quarters · filed 2020-05-07 | |||
| 2018-12-31 | $471.77K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $386.93K derived: sum of 2 quarters · filed 2020-03-11 | $373.69K derived: sum of 3 quarters · filed 2020-03-11 | $110.92K 10-K · filed 2020-03-11 | -$58.37K 10-K · filed 2019-03-18 | |||
| 2018-09-30 | -$84.84K 10-Q · filed 2019-11-14 | -$98.08K derived: sum of 2 quarters · filed 2019-11-14 | -$360.85K 10-Q · filed 2019-11-14 | |||||
| 2018-06-30 | -$13.24K 10-Q · filed 2019-08-08 | -$276.01K 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | -$262.77K 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | $0.00 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |